{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:53:44Z","timestamp":1793357624941,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1842919N"],"award-info":[{"award-number":["1842919N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["C\/2020\/1380"],"award-info":[{"award-number":["C\/2020\/1380"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ekir.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T23:11:22Z","timestamp":1655248282000},"page":"1939-1950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-9675","authenticated-orcid":false,"given":"Ben","family":"Sprangers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart M.","family":"Lichtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell H.","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2022.06.005_bib1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ekir.2022.06.005_bib2","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","article-title":"Cancer and renal insufficiency results of the BIRMA study","volume":"103","author":"Janus","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ekir.2022.06.005_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/14740338.2018.1477937","article-title":"Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities","volume":"17","author":"Gonzalez","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ekir.2022.06.005_bib4","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/sj.ki.5001934","article-title":"The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease","volume":"70","author":"Charytan","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.06.005_bib5","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1681\/ASN.2020060877","article-title":"The exclusion of patients with CKD in prospectively registered interventional trials for COVID-19-a rapid review of international registry data","volume":"31","author":"Major","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.06.005_bib6","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.2018.7260","article-title":"Representation of patients with chronic kidney disease in trials of cancer therapy","volume":"319","author":"Kitchlu","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2022.06.005_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO.19.02138","article-title":"Improving cancer care for patients with chronic kidney disease","volume":"38","author":"Sprangers","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2022.06.005_bib8","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib9","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2022.06.005_bib10","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib11","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in Type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2022.06.005_bib12","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US renal data system 2020 annual data report: epidemiology of kidney disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.06.005_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.ajkd.2021.02.003","article-title":"Racial and ethnic disparities in excess deaths among persons with kidney failure during the COVID-19 pandemic, March\u2013July 2020","volume":"77","author":"Kim","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.06.005_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/j.ajkd.2013.03.009","article-title":"Lifetime incidence of CKD stages 3\u20135 in the United States","volume":"62","author":"Grams","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.06.005_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.ajkd.2021.04.006","article-title":"Kidney-related research in the United States: a position statement from the National Kidney Foundation and the American Society of Nephrology","volume":"78","author":"Murray","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.06.005_bib16","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2215\/CJN.17561120","article-title":"Understanding and overcoming the challenges related to cardiovascular trials involving patients with kidney disease","volume":"16","author":"Ishida","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.06.005_bib17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.ekir.2022.06.005_bib18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/ndt\/gfz182","article-title":"Sudden cardiac death in dialysis patients: different causes and management strategies","volume":"36","author":"Genovesi","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.06.005_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000301","article-title":"Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan","volume":"3","author":"Funakoshi","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.ekir.2022.06.005_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mds344","article-title":"Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study","volume":"24","author":"Janus","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ekir.2022.06.005_bib21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00134-017-4950-6","article-title":"Contrast-associated acute kidney injury is a myth: yes","volume":"44","author":"Ehrmann","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00134-017-5015-6","article-title":"Contrast-associated acute kidney injury is a myth: no","volume":"44","author":"Weisbord","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00134-017-4970-2","article-title":"Contrast-associated acute kidney injury is a myth: we are not sure","volume":"44","author":"Kashani","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1148\/radiol.2019192094","article-title":"Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation","volume":"294","author":"Davenport","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2022.06.005_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1148\/radiol.2020202903","article-title":"Use of intravenous gadolinium-based contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation","volume":"298","author":"Weinreb","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2022.06.005_bib26","first-page":"285","article-title":"Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol","volume":"3","author":"Elmholdt","year":"2010","journal-title":"NDT Plus"},{"key":"10.1016\/j.ekir.2022.06.005_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082037","article-title":"Nephrogenic systemic fibrosis in Denmark--a nationwide investigation","volume":"8","author":"Elmholdt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2022.06.005_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","article-title":"Risk of nephrogenic systemic fibrosis in patients with Stage 4 or 5 chronic kidney disease receiving a Group II gadolinium-based contrast agent: a systematic review and meta-analysis","volume":"180","author":"Woolen","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1148\/radiol.12121394","article-title":"Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material","volume":"267","author":"Davenport","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2022.06.005_bib30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1148\/radiol.13122276","article-title":"Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate","volume":"268","author":"Davenport","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2022.06.005_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1148\/radiol.12121460","article-title":"Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis","volume":"267","author":"McDonald","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2022.06.005_bib32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1148\/radiol.12121823","article-title":"Intravenous contrast material-induced nephropathy: causal or coincident phenomenon?","volume":"267","author":"McDonald","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2022.06.005_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1148\/radiol.13130775","article-title":"Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate","volume":"271","author":"McDonald","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2022.06.005_bib34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2214\/AJR.17.19499","article-title":"Propensity score matching as a substitute for randomized controlled trials on acute kidney injury after contrast media administration: a systematic review","volume":"211","author":"Dekkers","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ekir.2022.06.005_bib35","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2214\/AJR.14.14259","article-title":"Contrast media controversies in 2015: imaging patients with renal impairment or risk of contrast reaction","volume":"204","author":"Davenport","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ekir.2022.06.005_bib36","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2214\/AJR.13.11369","article-title":"The challenges in assessing contrast-induced nephropathy: where are we now?","volume":"202","author":"Davenport","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ekir.2022.06.005_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1148\/radiol.10092000","article-title":"Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe?","volume":"256","author":"Katzberg","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2022.06.005_bib38","series-title":"Considerations in the selection of a new gadolinium-based contrast agent","author":"Tweedle","year":"2014"},{"key":"10.1016\/j.ekir.2022.06.005_bib39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1148\/radiol.2019182916","article-title":"A\u00a0systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis","volume":"292","author":"Attari","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2022.06.005_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-221016","article-title":"A\u00a0unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR","volume":"2017","author":"Lohani","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ekir.2022.06.005_bib41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1148\/radiol.2020201492","article-title":"Risk of nephrogenic systemic fibrosis in Stage 4 and 5 chronic kidney disease following Group II gadolinium-based contrast agent administration: subanalysis by chronic kidney disease stage","volume":"297","author":"Shankar","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.ekir.2022.06.005_bib42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.06.005_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2018050515","article-title":"Quantity and reporting quality of kidney research","volume":"30","author":"Chatzimanouil","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.06.005_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference","volume":"92","author":"Baigent","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.06.005_bib45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41581-019-0212-x","article-title":"Kidney disease trials for the 21st century: innovations in design and conduct","volume":"16","author":"Herrington","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2022.06.005_bib46","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1200\/JCO.2015.62.6341","article-title":"Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with Breast Cancer: Alliance A171201, an ancillary study of CALGB\/CTSU 49907","volume":"34","author":"Lichtman","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2022.06.005_bib47","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2022.06.005_bib48","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1681\/ASN.2020060833","article-title":"Prediction of kidney drug clearance: a comparison of tubular secretory clearance and glomerular filtration rate","volume":"32","author":"Chen","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.06.005_bib49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.ajkd.2005.08.038","article-title":"Renal function testing","volume":"47","author":"Rosner","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.06.005_bib50","first-page":"273","article-title":"Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines","volume":"10","author":"Paglialunga","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ekir.2022.06.005_bib51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00432-005-0679-7","article-title":"Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge","volume":"131","author":"Holweger","year":"2005","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.ekir.2022.06.005_bib52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00440953","article-title":"Comparative assessment of techniques for estimation of glomerular filtration rate with 99mTc-DTPA","volume":"11","author":"Fawdry","year":"1985","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s003300100864","article-title":"Contrast media as markers of GFR","volume":"12","author":"Frennby","year":"2002","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ekir.2022.06.005_bib54","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2215\/CJN.11721018","article-title":"Estimation of kidney function in oncology: implications for anticancer drug selection and dosing","volume":"14","author":"Casal","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.06.005_bib55","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib57","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2011.468","article-title":"Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality","volume":"305","author":"Peralta","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2022.06.005_bib58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1681\/ASN.2010050483","article-title":"Cystatin C identifies chronic kidney disease patients at higher risk for complications","volume":"22","author":"Peralta","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.06.005_bib59","first-page":"1","article-title":"2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.06.005_bib60","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJMms2004740","article-title":"Hidden in plain sight - reconsidering the use of race correction in clinical algorithms","volume":"383","author":"Vyas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101197","article-title":"Evaluating the impact and rationale of race-specific estimations of kidney function: estimations from U.S. Nhanes, 2015\u20132018","volume":"42","author":"Tsai","year":"2021","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.ekir.2022.06.005_bib62","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib63","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1681\/ASN.2021070988","article-title":"A\u00a0unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease","volume":"32","author":"Delgado","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.06.005_bib64","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A\u00a0unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.06.005_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55833-0","article-title":"Agreement and precision analyses of various estimated glomerular filtration rate formulae in cancer patients","volume":"9","author":"Chancharoenthana","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ekir.2022.06.005_bib66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clgc.2011.10.004","article-title":"Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer","volume":"10","author":"Tsao","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ekir.2022.06.005_bib67","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2005.04.3091","article-title":"Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer","volume":"24","author":"Raj","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2022.06.005_bib68","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2017.72.7578","article-title":"New model for estimating glomerular filtration rate in patients with cancer","volume":"35","author":"Janowitz","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2022.06.005_bib69","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejca.2013.12.021","article-title":"Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma","volume":"50","author":"Shepherd","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ekir.2022.06.005_bib70","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ygyno.2020.03.017","article-title":"Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care","volume":"157","author":"McLean","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ekir.2022.06.005_bib71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.34067\/KID.0000572020","article-title":"Comparison of equations to estimate glomerular filtration rate and their impact on frequency of cisplatin-associated acute kidney injury","volume":"2","author":"Motwani","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2022.06.005_bib72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1475-097X.2006.00718.x","article-title":"The origin of the 1 x 73-m2 body surface area normalization: problems and implications","volume":"27","author":"Heaf","year":"2007","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1016\/j.ekir.2022.06.005_bib73","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/gfm662","article-title":"Glomerular filtration rate--what is the rationale and justification of normalizing GFR for body surface area?","volume":"23","author":"Geddes","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.06.005_bib74","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/ndt\/gfh983","article-title":"Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example","volume":"20","author":"Delanaye","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.06.005_bib75","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI100206","article-title":"Studies of urea excretion. II: relationship between urine volume and the rate of urea excretion by normal adults","volume":"6","author":"Moller","year":"1928","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.06.005_bib76","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0735-1097(98)00240-X","article-title":"The associations of body size and body composition with left ventricular mass: impacts for indexation in adults","volume":"32","author":"Hense","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2022.06.005_bib77","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/ndt\/gfp116","article-title":"Nephron number and individual glomerular volumes in male Caucasian and African American subjects","volume":"24","author":"Zimanyi","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.06.005_bib78","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10157-017-1448-z","article-title":"Guidelines for treatment of renal injury during cancer chemotherapy 2016","volume":"22","author":"Horie","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2022.06.005_bib79","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2008.09.012","article-title":"Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study","volume":"70","author":"Launay-Vacher","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ekir.2022.06.005_bib80","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","article-title":"Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study","volume":"22","author":"Christiansen","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ekir.2022.06.005_bib81","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2011.294","article-title":"A\u00a0portable fiberoptic ratiometric fluorescence analyzer provides rapid point-of-care determination of glomerular filtration rate in large animals","volume":"81","author":"Wang","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.06.005_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104417","article-title":"Next tier in\u00a0vitro and in\u00a0vivo nonclinical studies further elucidating the safety and toxicity profile of MB-102, a novel fluorescent tracer agent for measurement of glomerular filtration rate","volume":"107","author":"Dorshow","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.ekir.2022.06.005_bib83","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/TP.0b013e31820f42d9","article-title":"Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients","volume":"91","author":"Blosser","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2022.06.005_bib84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/21556660.2020.1854561","article-title":"Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients","volume":"10","author":"Watson","year":"2020","journal-title":"J\u00a0Drug Assess"},{"key":"10.1016\/j.ekir.2022.06.005_bib85","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2012.04004.x","article-title":"Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer","volume":"12","author":"Campbell","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2022.06.005_bib86","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A\u00a0multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.06.005_bib87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A\u00a0pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.06.005_bib88","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-friends of cancer research joint research statement","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ekir.2022.06.005_bib89","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jamia\/ocaa276","article-title":"Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials","volume":"28","author":"Kim","year":"2021","journal-title":"J\u00a0Am Med Inform Assoc"},{"key":"10.1016\/j.ekir.2022.06.005_bib90","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","article-title":"Evaluating eligibility criteria of oncology trials using real-world data and AI","volume":"592","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2022.06.005_bib91","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jgo.2016.11.001","article-title":"Enrollment of older adults on oncology trials: an FDA perspective","volume":"8","author":"Singh","year":"2017","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.ekir.2022.06.005_bib92","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2022.06.005_bib93","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ekir.2022.06.005_bib94","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4732","article-title":"Comparison of clinical characteristics between clinical trial participants and nonparticipants using electronic health record data","volume":"4","author":"Rogers","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ekir.2022.06.005_bib95","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00280-021-04308-z","article-title":"A\u00a0phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine\/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment","volume":"88","author":"Saif","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ekir.2022.06.005_bib96","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.ajkd.2021.08.018","article-title":"Research Priorities for Kidney-Related Research-An Agenda to Advance Kidney Care: A Position Statement From the National Kidney Foundation","volume":"79","year":"2022","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922014474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922014474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:41:30Z","timestamp":1762832490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922014474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":96,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2468024922014474"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2022.06.005","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}